Knowledge base
1,477 claims across 14 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,477ai alignment 361internet finance 291health 269space development 201entertainment 162grand strategy 121energy 23mechanisms 18collective intelligence 14robotics 5manufacturing 5critical systems 3unknown 3teleological economics 1
Legible immediate harm enforces governance convergence independent of competitive incentives because OpenAI implemented access restrictions on GPT-5.5 Cyber identical to Anthropic's Mythos restrictions within weeks of publicly criticizing Anthropic's approach
On April 7, 2026, Anthropic announced restricted access to Mythos through Project Glasswing. Sam Altman publicly criticized this as 'fear-based marketing' and accused Anthropic of 'exaggerating risks to keep control of its technology.' Within weeks, OpenAI announced GPT-5.5 Cyber with an identical r
Platform revenue share structures (55% YouTube, 8% TikTok) create structural pressure for creators to diversify into complement revenue streams where platforms take 0-30%
YouTube's 55% creator share on long-form ad revenue is the most favorable split among major platforms (TikTok ~8%, Instagram ~0%). However, YouTube still captures 45% of a $40B+ ad revenue pool, representing $18B+ annually in platform capture. This creates a structural incentive for creators to mone
Speculation-first community-owned models fail at 90%+ rate when speculative fundraising precedes product-market fit
Caladan Research documented that more than 90% of Web3 games effectively died after a $15 billion investment boom, with funding to studios collapsing 93% by 2025. The root cause was structural: studios raised tens or hundreds of millions of dollars before shipping viable products, removing the press
Web3 gaming peak adoption of 12% indicates speculative boom was confined to crypto-native users not mainstream audiences
At the height of the Web3 gaming boom, only 12% of gamers had tried a crypto game according to Coda Labs survey data. This means that even during peak speculation and maximum marketing investment, barely 1 in 8 gamers engaged with the category. The speculative boom was entirely internal to crypto en
Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm
The 'Ozempic personality' phenomenon reveals a narrative framing problem: patients widely report 'food noise quiet' as a positive liberation from obsessive food thoughts, while the same dopaminergic suppression mechanism causes reduced interest in social activities, sex, music, and pleasure generall
GLP-1 adolescent prescribing requires eating disorder screening because subclinical restrictive behaviors are clinically invisible without structured assessment
This case report documents an adolescent prescribed semaglutide who developed severe atypical anorexia nervosa with life-threatening cardiac complications (bradycardia 38 bpm, pericardial effusion) within 6 months. The critical finding is that 18 months of pre-prescription restrictive behaviors—incr
GLP-1 anhedonia mechanism undermines social engagement and meaning as non-clinical health determinants even while treating metabolic disease
Clinicians are reporting a pattern they call 'Ozempic personality' where GLP-1 patients experience reduced interest not just in food but in social activities, sex, music, and other pleasurable activities. The mechanism is the same VTA dopamine circuit suppression that makes GLP-1 effective for addic
GLP-1 prescribing creates systematic screening gap for atypical anorexia because normal BMI masks active restrictive psychopathology
Dr. Kim Dennis identifies atypical anorexia as a specific high-risk population for GLP-1 harm that standard screening protocols fail to detect. Atypical anorexia nervosa is characterized by meeting full diagnostic criteria for anorexia nervosa—including restrictive eating patterns, fear of weight ga
Expert divergence on GLP-1 eating disorder causality reflects fundamental evidence gap between clinical pattern recognition and epidemiological confirmation
Dr. Aaron Keshen reports EDs developing 'in people who take drugs as prescribed' supporting direct causality, while Dr. Anjali Pandit states 'not seeing this frequently' suggesting prescriber screening matters significantly. This is not a scientific debate about interpretation of shared data — it's
GLP-1 eating disorder risk doubles with prior mental health history creating identifiable high-risk population
The ISPOR study analyzed over 60,000 GLP-1 users and found cumulative eating disorder incidence of 1.275% across all users, with a critical stratification: GLP-1 users with prior mental health conditions had MORE THAN DOUBLE the eating disorder risk compared to GLP-1 users without mental health hist
GLP-1 eating disorder screening lacks reimbursement infrastructure despite identified risk population
Despite evidence of elevated eating disorder risk in GLP-1 users with prior mental health conditions, the prescribing infrastructure lacks systematic screening protocols. Timmerman Report documents that: (1) no standard protocol for eating disorder screening before prescribing exists, (2) no safety
GLP-1 eating disorder screening protocol combining SCOFF questionnaire, recent ED history review, and compensatory behavior assessment is recommended for pre-treatment risk stratification
The systematic review identifies a specific pre-treatment screening protocol for GLP-1 receptor agonist prescribing: (1) SCOFF questionnaire administration, (2) recent ED history review, (3) assessment for compensatory behaviors, and (4) weight-suppression history evaluation. This represents a clini
GLP-1 harm risk is mediated by cultural weight stigma and pressure rather than pharmacological properties alone
Robyn Pashby articulates the dual-truth framework: 'GLP-1s are legitimate evidence-based treatments for obesity, but they also sit inside our culture, which has intense weight pressure, weight stigma and eating disorder risk.' This positions harm not as inherent to the drug but as emergent from the
GLP-1-induced GI side effects may reinforce pre-existing purging cycles but no clinical evidence supports de novo eating disorder induction in patients without behavioral vulnerability
This systematic review provides the strongest current evidence synthesis on GLP-1 receptor agonists and eating disorder risk. The review explicitly states: 'To date, no clinical evidence links GLP-1RA use to the onset or worsening of AN.' This is a definitive closure of the de novo causation hypothe
GLP-1-mediated caloric deficit may trigger starvation-response restriction through neurobiological misinterpretation of pharmacological appetite suppression as famine
Multiple clinicians quoted in NBC News describe a progression pattern: beneficial appetite suppression → pathological restriction → 'atypical anorexia nervosa' presentation. The proposed mechanism is that the brain 'may interpret dramatic sudden weight loss as starvation, triggering obsessive food t
Semaglutide silences AgRP starvation-protection neurons, amplifying the relative importance of behavioral and social factors in determining eating disorder risk
Northwestern researchers identified a 'double whammy' mechanism for semaglutide's appetite suppression: it both signals fullness through standard GLP-1R agonism AND silences AgRP neurons that normally activate during negative energy balance to protect against starvation. Dr. Beutler describes AgRP n
CFTC ANPRM comment record closes with 1,500+ submissions and zero governance market mentions, suggesting NPRM will be calibrated to sports/election event contract patterns
The CFTC ANPRM comment period closed April 30, 2026 with 1,500+ public submissions—double the 800+ count from mid-April. Despite this high comment density, 37 sessions of tracking found zero mentions of futarchy, governance markets, decision markets, MetaDAO, or TWAP settlement mechanisms. The ANPRM
Third Circuit DCM preemption requires federal registration creating jurisdictional prerequisite not universal protection
The Third Circuit's preemption holding is jurisdictionally specific, not categorically protective. Holland & Knight's analysis quotes the court directly: 'Without federal registration as a designated contract market, the preemption framework would not apply.' The court defined the preempted field na
FCC Chair Carr's rebuke of Amazon's orbital debris objections applies competitive market logic to a commons governance problem, treating Kessler Syndrome risk as a competitive standing question rather than a planetary externality
On March 11, 2026, FCC Chair Brendan Carr publicly rebuked Amazon's opposition to SpaceX's 1 million satellite application, stating: 'Amazon should focus on the fact that it will fall roughly 1,000 satellites short of meeting its upcoming deployment milestone, rather than spending their time and res
SpaceX's waiver requests for standard processing rounds, milestone requirements, and surety bonds reveal a regulatory strategy to claim orbital spectrum priority without demonstrating deployment capability
SpaceX's January 30, 2026 FCC filing for up to 1 million satellites requested three specific waivers: (a) standard processing rounds, (b) NGSO milestone requirements and 6-year/9-year deployment obligations, and (c) surety bond requirements. These waivers are structurally significant because they ex
The alignment tax operates as a market-clearing mechanism in military AI procurement where safety-constrained labs lose contracts to unconstrained competitors regardless of internal opposition
The Google-Pentagon deal provides the third empirical data point confirming the alignment tax operates as a market-clearing mechanism. Anthropic refused Pentagon's 'all lawful purposes' demand in February 2026, maintaining three red lines: no autonomous weapons, no domestic surveillance, no high-sta
EU AI Act high-risk enforcement deadline became legally active April 28, 2026 when the Omnibus trilogue failed, creating the first mandatory AI governance enforcement date in history without a legislative escape clause
The second political trilogue on the Digital Omnibus for AI collapsed on April 28, 2026 after 12 hours of negotiations. The structural failure centered on conformity-assessment architecture for Annex I products (AI embedded in medical devices, machinery, diagnostics, vehicles). Parliament wanted sec
EU AI Act military exclusion gap means the most consequential frontier AI deployments remain outside mandatory governance scope even if civilian enforcement occurs
The EU AI Act explicitly excludes military AI systems from its scope. This creates a fundamental governance gap: even if August 2, 2026 enforcement happens for civilian high-risk systems, the most consequential AI deployments—Pentagon systems, classified military applications, autonomous weapons—are
Governance instrument instrumentalization represents a distinct failure mode where safety-adjacent regulatory authority retains formal validity while its function inverts from public safety enforcement to commercial negotiation leverage
The Pentagon's Anthropic designation reveals a governance failure mode distinct from the existing Mode 1-5 taxonomy: **governance instrument instrumentalization**—where safety-adjacent regulations are deliberately used as commercial negotiation tools rather than for stated public safety purposes.
Internal employee governance fails to constrain frontier AI military deployment because 580+ employees including senior technical researchers could not prevent a classified AI deployment they characterized as harmful
The Google-Pentagon deal reveals a critical failure mode in employee governance as an alignment mechanism. On April 27, 2026, 580+ Google employees—including 20+ directors/VPs and senior DeepMind researchers—sent a letter to CEO Sundar Pichai urging rejection of the classified Pentagon AI deal. The
Page 2 of 60